store at low temperature,keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RMC-7977 is a reversible triple complex RAS inhibitor that exhibits broad-spectrum activity against mutant and wild-type (WT) variants of KRAS, NRAS, and HRAS. The compound is capable of triggering tumor regression and has shown good tolerability in a variety of RAS-dependent preclinical cancer models. In addition, RMC-7977 effectively inhibited the growth of KRASG12C cancer tumor models.[1]
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 1,930.00 | |
5 mg | In stock | $ 4,086.00 | |
10 mg | In stock | Inquiry |
Description | RMC-7977 is a reversible triple complex RAS inhibitor that exhibits broad-spectrum activity against mutant and wild-type (WT) variants of KRAS, NRAS, and HRAS. The compound is capable of triggering tumor regression and has shown good tolerability in a variety of RAS-dependent preclinical cancer models. In addition, RMC-7977 effectively inhibited the growth of KRASG12C cancer tumor models.[1] |
In vitro |
METHODS: U2OS cells were treated with 50 nM RMC-7977 to observe the formation of KRAS-CYPA complexes and disruption of KRAS(G12V)-CRAF interactions using a live-cell nano-bioluminescence resonance energy transfer (BRET) kinetic assay.
RESULTS: RMC-7977 induced KRAS and CYPA binding and dissociated the CRAF RBD from KRAS at the same fast rate (signaling half-life (t1/2) < 5 min).[1] METHODS: RAS-dependent (KRAS, NRAS, or EGFR mutated) cancer cells treated with RMC-7977 (0.1,1,10,100,100 nM) were compared for activity of RMC-7977 in cancer cells harboring various activating mutations in the RAS pathway, specifically oncogenic variants of KRAS, NRAS, EGFR, or BRAF. RESULTS: Exhibited concentration-dependent inhibition of downstream signaling and proliferation in the low nanomolar range.[1] |
In vivo |
METHODS: U2OS cells were treated with 50 nM RMC-7977 to observe the formation of KRAS-CYPA complexes and disruption of KRAS(G12V)-CRAF interactions using a live-cell nano-bioluminescence resonance energy transfer (BRET) kinetic assay.
RESULTS: RMC-7977 induced KRAS and CYPA binding and dissociated the CRAF RBD from KRAS at the same fast rate (signaling half-life (t1/2) < 5 min).[1] METHODS: RAS-dependent (KRAS, NRAS, or EGFR mutated) cancer cells treated with RMC-7977 (0.1,1,10,100,100 nM) were compared for activity of RMC-7977 in cancer cells harboring various activating mutations in the RAS pathway, specifically oncogenic variants of KRAS, NRAS, EGFR, or BRAF. RESULTS: Exhibited concentration-dependent inhibition of downstream signaling and proliferation in the low nanomolar range.[1] |
Molecular Weight | 865.09 |
Formula | C47H60N8O6S |
CAS No. | 2765082-12-8 |
store at low temperature,keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
RMC-7977 2765082-12-8 GPCR/G Protein MAPK Ras inhibitor inhibit